Addendum
Talazoparib (breast cancer) - Addendum to Commission A20-48
Report documents
-
Addendum
Talazoparib (breast cancer) - Addendum to Commission A20-48
Dossier assessment
Indication:
| Adults with BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer |
Result of dossier assessment:
| Conclusion of dossier assessment A20-48 unchanged: hint of considerable added benefit |
Project details
- Project no.
- A20-89
- Commission
- Commission awarded on 06.10.2020 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed